Kanada - engelska - Health Canada

homeocan inc. - fraxinus excelsior - globules - 1x - fraxinus excelsior 1x - homeopathic products

Kanada - engelska - Health Canada

dolisos canada inc. - fraxinus americana - globules - 1x - fraxinus americana 1x - homeopathic products

Kanada - engelska - Health Canada

dolisos canada inc. - fraxinus excelsior - globules - 1x - fraxinus excelsior 1x - homeopathic products

USA - engelska - NLM (National Library of Medicine)

alk-abello, inc. - aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6), aspergillus repens (unii: sq89e6lome) (aspergillus repens - unii:sq89e6lome), aspergillus flavus var. oryzae (unii: q6z8uk5r3g) (aspergillus flavus var. oryzae - unii:q6z8uk5r3g), aspergillus terreus (unii: qbn8k7055x) (aspergillus terreus - unii:qbn8k7055x) - fraxinus americana pollen 0.05 g in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

USA - engelska - NLM (National Library of Medicine)

alk-abello, inc. - solidago canadensis pollen (unii: 644cz16ir5) (solidago canadensis pollen - unii:644cz16ir5) - equus caballus skin 20000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

USA - engelska - NLM (National Library of Medicine)

antigen laboratories, inc. - amaranthus retroflexus pollen (unii: 73b14px5fw) (amaranthus retroflexus pollen - unii:73b14px5fw), salsola kali pollen (unii: 2mh135kc6g) (salsola kali pollen - unii:2mh135kc6g), plantago lanceolata pollen (unii: do87t1u2ci) (plantago lanceolata pollen - unii:do87t1u2ci), carya illinoinensis pollen (unii: pyo4jr720y) (carya illinoinensis pollen - unii:pyo4jr720y), carya alba pollen (unii: g2a764t54b) (carya alba pollen - unii:g2a764t54b), juniperus virginiana pollen (unii: py0ja16r2g) (juniperus virg - amaranthus retroflexus pollen 0.002 g in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

USA - engelska - NLM (National Library of Medicine)

antigen laboratories, inc. - poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), ambrosia trifida pollen (unii: ku1v1898xx) (ambrosia trifida pollen - unii:ku1v1898xx), ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3), ambrosia psilostachya pollen (unii: rx18m46k8l) (ambrosia psilostachya pollen - unii:rx18m46k8l), cynodon dactylon pollen (unii: 175f461w10) (cynodon dactylon pollen - unii:175f461w10), plantago lanceolata pollen (unii: do87t1u2ci) (p - poa pratensis pollen 160 [bau] in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

USA - engelska - NLM (National Library of Medicine)

antigen laboratories, inc. - plantago lanceolata pollen (unii: do87t1u2ci) (plantago lanceolata pollen - unii:do87t1u2ci), chenopodium album pollen (unii: 098lkx5ncn) (chenopodium album pollen - unii:098lkx5ncn), urtica dioica pollen (unii: dnb59m1nvu) (urtica dioica pollen - unii:dnb59m1nvu), amaranthus retroflexus pollen (unii: 73b14px5fw) (amaranthus retroflexus pollen - unii:73b14px5fw), ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3), rumex acetosella pollen (unii: n52miq81 - plantago lanceolata pollen 0.002 g in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

USA - engelska - NLM (National Library of Medicine)

antigen laboratories, inc. - plantago lanceolata pollen (unii: do87t1u2ci) (plantago lanceolata pollen - unii:do87t1u2ci), chenopodium album pollen (unii: 098lkx5ncn) (chenopodium album pollen - unii:098lkx5ncn), urtica dioica pollen (unii: dnb59m1nvu) (urtica dioica pollen - unii:dnb59m1nvu), amaranthus retroflexus pollen (unii: 73b14px5fw) (amaranthus retroflexus pollen - unii:73b14px5fw), ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3), rumex acetosella pollen (unii: n52miq81 - plantago lanceolata pollen 0.002 g in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

USA - engelska - NLM (National Library of Medicine)

antigen laboratories, inc. - felis catus hair (unii: 1564hd0n96) (felis catus hair - unii:1564hd0n96), cynodon dactylon pollen (unii: 175f461w10) (cynodon dactylon pollen - unii:175f461w10), phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3), iva annua var. annua pollen (unii: y2u5s5pf22) (iva annua var. annua pollen - unii:y2u5s5pf22), fraxinus americana pollen (unii: g684lx721q) (fraxinus ameri - felis catus hair 2000 [bau] in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski